DB:82C

Stock Analysis Report

Executive Summary

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products.


Snowflake Analysis

Exceptional growth potential and fair value.


Similar Companies

Share Price & News

How has Circassia Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 82C's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

20.2%

82C

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

-58.3%

82C

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 82C underperformed the German Biotechs industry which returned -8.1% over the past year.

Return vs Market: 82C underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

82CIndustryMarket
7 Day20.2%11.7%9.9%
30 Day-30.5%-5.9%-16.6%
90 Day-27.7%-22.6%-24.8%
1 Year-58.3%-58.3%-7.9%-8.1%-15.0%-17.5%
3 Year-88.1%-88.1%16.6%15.4%-17.4%-24.5%
5 Year-96.4%-96.4%-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is Circassia Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Circassia Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 82C (€0.15) is trading below our estimate of fair value (€2.19)

Significantly Below Fair Value: 82C is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 82C is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 82C is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 82C's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 82C is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Circassia Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

60.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 82C is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: 82C is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 82C's is expected to become profitable in the next 3 years.

Revenue vs Market: 82C's revenue (23.3% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: 82C's revenue (23.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 82C's Return on Equity is forecast to be high in 3 years time (26.6%)


Next Steps

Past Performance

How has Circassia Pharmaceuticals performed over the past 5 years?

-9.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 82C is currently unprofitable.

Growing Profit Margin: 82C is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 82C is unprofitable, and losses have increased over the past 5 years at a rate of -9% per year.

Accelerating Growth: Unable to compare 82C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 82C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 82C has a negative Return on Equity (-51.65%), as it is currently unprofitable.


Next Steps

Financial Health

How is Circassia Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 82C's short term assets (£44.0M) do not cover its short term liabilities (£109.5M).

Long Term Liabilities: 82C's short term assets (£44.0M) do not cover its long term liabilities (£103.7M).


Debt to Equity History and Analysis

Debt Level: 82C's debt to equity ratio (19.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if 82C's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 82C has a low level of unsold assets or inventory.

Debt Coverage by Assets: 82C's debt is covered by short term assets (assets are 2.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 82C has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 82C has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Circassia Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 82C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 82C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 82C's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 82C's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 82C's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Circassia Pharmaceuticals has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Roderick Hafner
Senior Vice President of Research & Development12yrsUK£464.00kno data
Ian Johnson
Executive Chairman0.25yrno datano data
Michael Roy Roller
CFO & Director0.17yrno datano data
Jonathan Emms
COO & Executive Director0.50yrno data0.080% £57.0k
Nina Kataria
Senior Vice President Global Human Resources5.75yrsno datano data
David Acheson
Senior Vice President of US Commercial3.17yrsno datano data
Darren Mercer
Senior Vice President of EU & RoW Commercialno datano datano data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Management: 82C's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ian Johnson
Executive Chairman0.25yrno datano data
Michael Roy Roller
CFO & Director0.17yrno datano data
Jonathan Emms
COO & Executive Director0.50yrno data0.080% £57.0k
Garry Watts
Senior Independent Directorno datano datano data
Le Jo
Non-Executive Director2yrsUK£55.00kno data
Sharon Curran
Non-Executive Director2yrsUK£49.00kno data

0.5yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 82C's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.1%.


Top Shareholders

Company Information

Circassia Pharmaceuticals plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Circassia Pharmaceuticals plc
  • Ticker: 82C
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£63.319m
  • Listing Market Cap: UK£71.198m
  • Shares outstanding: 374.67m
  • Website: https://www.circassia.com

Number of Employees


Location

  • Circassia Pharmaceuticals plc
  • Northbrook House
  • Robert Robinson Avenue
  • Oxford
  • Oxfordshire
  • OX4 4GA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CIRAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2014
82CDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2014
CSSP.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMar 2014
82CBRSE (Berne Stock Exchange)YesOrdinary SharesCHCHFMar 2014

Biography

Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through NIOX and US AZ Collaboration segments. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD). Its pipeline products include Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD; and AirNOvent, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, and Germany, as well as through a network of partners internationally. It has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to AirNOvent. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 23:37
End of Day Share Price2020/03/30 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.